Foghorn Therapeutics (FHTX) Cash from Financing Activities (2019 - 2026)

Foghorn Therapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $49.8 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 35707.19% year-over-year to $49.8 million; the TTM figure through Mar 2026 stood at $50.7 million (down 51.48% YoY), while the FY2025 annual figure was $1.0 million, down 99.03% from the prior year.
• Cash from Financing Activities was $49.8 million for Q1 2026 at Foghorn Therapeutics, up from $581000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $103.2 million in Q2 2024 to a low of $4000.0 in Q4 2024.
• Historically, Cash from Financing Activities has averaged $9.4 million across 5 years, with a median of $333000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 99.93% in 2022, then soared 100100.0% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $16000.0 in 2022, then jumped by 1062.5% to $186000.0 in 2023, then slumped by 97.85% to $4000.0 in 2024, then soared by 14425.0% to $581000.0 in 2025, then soared by 8466.61% to $49.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $49.8 million (Q1 2026), $581000.0 (Q4 2025), and $49000.0 (Q3 2025), per Business Quant data.